Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 10, 2004. The document primarily reports on corporate actions regarding share buybacks and updates on directors' interests in company shares held through various employee benefit trusts and plans.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The financial data present relates exclusively to share repurchase transactions and treasury holdings:
- Share Buyback (August 9, 2004): 750,000 shares purchased at 1,060.03 pence per share.
- Share Buyback (August 6, 2004): 950,000 shares purchased at 1,076.8931 pence per share.
- Treasury Holdings (Post-August 9): 31,718,000 shares held in Treasury.
- Shares in Issue (Post-August 9): 5,902,323,254 shares (excluding Treasury shares).
- US Retirement Plan Movement: Fund holdings increased from 19,033,495 to 19,179,793 ADRs at an average price of $40.95.
Material Changes
The primary material changes reported are the reduction in outstanding shares due to treasury purchases and minor adjustments in directors' beneficial interests via employee trusts:
- Capital Structure: The company executed two buyback transactions in early August 2004, reducing the number of shares in issue and increasing treasury holdings.
- Directors' Interests:
- 122 ADRs were transferred from the GSK US Trust to a Performance Share Plan participant.
- 514 Ordinary shares were transferred from the SmithKline Beecham Employee Benefit Trust to an Annual Investment Plan participant.
- Directors Dr. J-P Garnier and Dr. T Yamada hold indirect interests via the GSK US Trust and the US Retirement Savings Plan.
- Director John Coombe holds an indirect interest via the SmithKline Beecham Employee Benefit Trust.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a procedural report of share transactions and regulatory disclosures regarding director interests.
Investor Verification Checklist
- Verify the total cost of the August 6 and August 9 share repurchases against the company's cash position in the most recent quarterly report.
- Confirm the updated total number of shares in issue (5,902,323,254) for accurate earnings per share calculations.
- Review the specific terms of the GSK US Trust and SmithKline Beecham Employee Benefit Trust to understand the extent of directors' indirect exposure.
- Check subsequent filings to determine if the remaining authority from the May 17, 2004 Annual General Meeting was utilized for further buybacks.